Annexon Inc
NASDAQ:ANNX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Ultrapar Participacoes SA
BOVESPA:UGPA3
|
BR |
Annexon Inc
Other Liabilities
Annexon Inc
Other Liabilities Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Other Liabilities | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Annexon Inc
NASDAQ:ANNX
|
Other Liabilities
$23.3m
|
CAGR 3-Years
-10%
|
CAGR 5-Years
88%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Other Liabilities
$32.6B
|
CAGR 3-Years
2%
|
CAGR 5-Years
3%
|
CAGR 10-Years
24%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Other Liabilities
$2.1B
|
CAGR 3-Years
-26%
|
CAGR 5-Years
-27%
|
CAGR 10-Years
2%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Other Liabilities
$5.1B
|
CAGR 3-Years
-16%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
4%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Other Liabilities
$3B
|
CAGR 3-Years
41%
|
CAGR 5-Years
36%
|
CAGR 10-Years
51%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Other Liabilities
$2.2B
|
CAGR 3-Years
47%
|
CAGR 5-Years
24%
|
CAGR 10-Years
11%
|
|
Annexon Inc
Glance View
Annexon, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, eye and brain. The company is headquartered in Brisbane California, California and currently employs 61 full-time employees. The company went IPO on 2020-07-24. The firm is engaged in developing complement medicines for patients suffering from serious complement-mediated autoimmune, neurodegenerative and ophthalmic disorders. Its pipeline includes three clinical-stage assets across three therapeutic franchises: Autoimmune, Neurodegeneration and Ophthalmology. Its lead candidate, ANX005, is a monoclonal antibody formulated for intravenous administration for several autoimmune indications. ANX005 is being evaluated in a Phase II/III clinical trial for the treatment of patients with Guillain-Barre Syndrome and a Phase II trial in patients with warm autoimmune hemolytic anemia. The company ANX009 clinical candidate is a subcutaneous formulation of an antigen-binding fragment, which is evaluates in a Phase I trial. The company is also developing ANX005, which is in Phase II trials in Huntington’s disease and amyotrophic lateral sclerosis. The firm's ANX007 program is a Fab formulated.
See Also
What is Annexon Inc's Other Liabilities?
Other Liabilities
23.3m
USD
Based on the financial report for Dec 31, 2025, Annexon Inc's Other Liabilities amounts to 23.3m USD.
What is Annexon Inc's Other Liabilities growth rate?
Other Liabilities CAGR 5Y
88%
Over the last year, the Other Liabilities growth was -10%. The average annual Other Liabilities growth rates for Annexon Inc have been -10% over the past three years , 88% over the past five years .
